Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized Study to Evaluate the Radiographic Efficacy and Safety of Enbrel (Etanercept) added to Methotrexate in Comparison with Usual Treatment in Subjects with Moderate Rheumatoid Arthritis Disease Activity

Trial Profile

An Open-Label, Randomized Study to Evaluate the Radiographic Efficacy and Safety of Enbrel (Etanercept) added to Methotrexate in Comparison with Usual Treatment in Subjects with Moderate Rheumatoid Arthritis Disease Activity

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etanercept (Primary) ; Ciclosporin; Gold; Hydroxychloroquine; Leflunomide; Methotrexate; Methotrexate; Methotrexate; Sulfasalazine
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms EXTRA
  • Sponsors Pfizer; Wyeth
  • Most Recent Events

    • 05 Oct 2021 This trial has been completed in Spain and France (End Date: 27 Jan 2010), according to European Clinical Trials Database record.
    • 10 Mar 2012 The trial status is recruiting in (Spain, France, United Kingdom), completed in (Denmark) as reported by European Clinical Trials Database.
    • 20 Jun 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top